Annals of translational medicine最新文献

{"title":"Practice of Fluid and Vasopressor Therapy in Critically Ill Invasively Ventilated Patients (PRoFLUID)-study protocol for an international multicenter observational cohort study.","authors":"","doi":"10.21037/atm-23-1957","DOIUrl":"10.21037/atm-23-1957","url":null,"abstract":"<p><strong>Background: </strong>The practice of intravenous fluid and vasopressor therapy in intensive care unit (ICU) patients, particularly in those who receive invasive ventilation, has been subject to change. Traditional approaches of 'early and liberal fluid administration' and 'late and restrictive vasopressor use' have been challenged, leading to recommendations for giving less fluids and earlier administration of vasopressors. Recommendations for fluid deresuscitation-active fluid removal-are absent. The global approach to fluid and vasopressor therapy in invasively ventilated patients is currently unclear. Our aim is to explore the practice of intravenous fluid and vasopressor therapy in invasively ventilated ICU patients in a study named 'Practice of Fluid and Vasopressor Therapy in Critically Ill Invasively Ventilated Patients' (PRoFLUID).</p><p><strong>Methods: </strong>PRoFLUID is an international, multicenter, observational cohort study in critically ill adult patients that are invasively ventilated for more than 24 hours. The outcomes include various aspects of fluid and vasopressor therapy, urine output and cumulative fluid balances. We will also collect duration of ventilation, lengths of stay and mortality in ICU and hospital. We expect to collect granular data on fluid and vasopressor therapy in a sample of at least 2,500 patients.</p><p><strong>Discussion: </strong>PRoFLUID will provide useful insights into the practice of fluid and vasopressor therapy in invasively ventilated critically ill patients. PRoFLUID also allows us to determine whether geo-economic differences in management of intravenous fluid and vasopressor therapy exist, and allows for analyses of associations of aspects of fluid and vasopressor therapy with outcomes. Last but not least, its findings could feed sample size calculations of future randomized clinical trials of fluid and vasopressor therapy. In conclusion, PRoFLUID will collect data on fluid and vasopressor therapy in invasively ventilated ICU patients worldwide, providing insights that will guide future clinical decisions and randomized trial designs.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov NCT05968066. Registered on August 1, 2023.</p><p><strong>Keywords: </strong>Intensive care; invasive ventilation; fluid therapy; fluid management; vasopressor.</p>","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"12 5","pages":"92"},"PeriodicalIF":0.0,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring volanesorsen: a promising approach to preventing acute pancreatitis in severe hypertriglyceridemia.","authors":"Julien Moury, Gauthier Nendumba, Arnaud Robert, Benedicte Hauqiert, Ovidiu Vornicu, Sydney Blackman, Emily Perriens, Maha Bendoumou, Anaïs Carrasco Sanchez, Emma Buttice, Amina El Bachti, David Vidal Bankier, Simrane Gurdina, Anne-Sophie Dincq, Patrick Evrard, Pierre Bulpa, Isabelle Michaux, Patrick M Honore","doi":"10.21037/atm-24-63","DOIUrl":"10.21037/atm-24-63","url":null,"abstract":"","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"12 5","pages":"101"},"PeriodicalIF":0.0,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abscopal effect induced by cryoablation in a 55-year-old patient with metastatic dedifferentiated liposarcoma: a case report.","authors":"Laureline Wetterwald, Sotirios Papadopoulos, Georgia Tsoumakidou, Sarah Boughdad, Daniela Ferraro, Pantelis Koulouris, Stephane Cherix, Rafael Duran, Antonia Digklia","doi":"10.21037/atm-23-1868","DOIUrl":"10.21037/atm-23-1868","url":null,"abstract":"<p><strong>Background: </strong>Metastatic dedifferentiated liposarcoma (DDLPS) is primarily managed with chemotherapy, yet with poor response rate. Locoregional therapies, such as radiotherapy and percutaneous cryoablation, can provide palliation for inoperable metastatic sarcomas. In rare instances, those ablative therapies can elicit an immune-mediated regression of untreated metastases in a process named the abscopal effect. With the growing use of immunotherapy, reports on the abscopal effect have become more frequent during the last decade.</p><p><strong>Case description: </strong>A 55-year-old patient with no prior medical history was diagnosed with a stage IV DDLPS. The patient was first treated with induction chemotherapy followed by <i>en bloc</i> resection and adjuvant radiotherapy. After two local relapses treated with chemotherapy, the patient developed a systemic disease progression. While progressing on immunochemotherapy, the patient underwent palliative percutaneous cryoablation. Three months after the procedure, the ¹⁸fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸FDG PET/CT) showed regression of the distant metastasis alongside the regression of the cryoablated tumor, suggesting an abscopal effect.</p><p><strong>Conclusions: </strong>The occurrence of the abscopal effect after progressive disease suggests that cryoablation triggered a systemic immune response, highlighting the potential of this treatment combination. However, it remains a rare phenomenon, and further research and clinical trials are required to determine optimal treatment sequencing.</p>","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"12 5","pages":"94"},"PeriodicalIF":0.0,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between sore throat and early immune responses against COVID-19 before and after the emergence of the Omicron variant.","authors":"Yusuke Takegoshi, Kentaro Nagaoka, Toshiki Kido, Hitoshi Kawasuji, Yushi Murai, Makito Kaneda, Kou Kimoto, Hideki Tani, Hideki Niimi, Yoshitomo Morinaga, Yoshihiro Yamamoto","doi":"10.21037/atm-24-36","DOIUrl":"10.21037/atm-24-36","url":null,"abstract":"<p><strong>Background: </strong>Sore throat is a prevalent symptom of coronavirus disease 2019 (COVID-19), particularly when caused by the Omicron variants. However, the association between sore throat and immune responses to different severe acute respiratory syndrome coronavirus 2 variants remains unclear. This study aimed to elucidate the characteristics of immune responses associated with sore throat in patients with COVID-19 before and after the emergence of Omicron.</p><p><strong>Methods: </strong>In this prospective observational study, we enrolled patients with COVID-19 hospitalized between December 2020 and April 2022, which covered the pre-Omicron and Omicron (BA.1 variant) endemic periods. Sore throat was assessed using a daily questionnaire, including an analog scale for sore throat grade (0 to 3) from admission until discharge. Serum levels of immune indicators were assessed using enzyme-linked immunosorbent assay.</p><p><strong>Results: </strong>A total of 47 patients infected with Omicron and 136 patients infected with preceding variants were included in the analyses. The frequency of sore throat was significantly higher in participants infected with Omicron than that in those infected with preceding variants (66% <i>vs.</i> 42%, P<0.005). Sore throat was associated with nasopharyngeal viral load, interleukin-6 (IL-6)/interferon-α (IFN-α) levels in participants infected with preceding variants, whereas, it was associated with age, the body mass index, and interferon-λ1 (IFN-λ1) in participants infected with Omicron.</p><p><strong>Conclusions: </strong>Infection with the Omicron variant is characterized by increased sore throat frequency and altered associations between sore throat and several immune indicators, including IFN-α, IL-6, and IFN-λ1.</p>","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"12 5","pages":"87"},"PeriodicalIF":0.0,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emergency tracheostomy management in critical care and the operating room.","authors":"Jonathan Graham, Louise Ellard, Timothy Makar, Param Pillai","doi":"10.21037/atm-24-43","DOIUrl":"10.21037/atm-24-43","url":null,"abstract":"","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"12 5","pages":"97"},"PeriodicalIF":0.0,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to ESM1 promotes triple-negative breast cancer cell proliferation through activating AKT/NF-κB/Cyclin D1 pathway.","authors":"","doi":"10.21037/atm-2024-9","DOIUrl":"10.21037/atm-2024-9","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.21037/atm-20-7005.].</p>","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"12 5","pages":"104"},"PeriodicalIF":0.0,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to lncRNA NFYC-AS1 promotes the development of lung adenocarcinomas through autophagy, apoptosis, and MET/c-Myc oncogenic proteins.","authors":"","doi":"10.21037/atm-2024-6","DOIUrl":"10.21037/atm-2024-6","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.21037/atm-21-4995.].</p>","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"12 5","pages":"105"},"PeriodicalIF":0.0,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to MiR-140-5p targets Prox1 to regulate the proliferation and differentiation of neural stem cells through the ERK/MAPK signaling pathway.","authors":"","doi":"10.21037/atm-2024-21","DOIUrl":"10.21037/atm-2024-21","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.21037/atm-21-597.].</p>","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"12 5","pages":"106"},"PeriodicalIF":0.0,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Has the CONVINCE trial convinced the nephrology and dialysis community?","authors":"Julien Moury, Gauthier Nendumba, Arnaud Robert, Benedicte Hauquiert, Ovidiu Vornicu, Sydney Blackman, Emily Perriens, Nathan De Lissnyder, Andriy Shchukin, Farah El Yaakoubi, Clara Saad, Cyril Schmit, Anne-Sophie Dincq, Patrick Evrard, Pierre Bulpa, Isabelle Michaux, Patrick M Honore","doi":"10.21037/atm-24-50","DOIUrl":"10.21037/atm-24-50","url":null,"abstract":"","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"12 5","pages":"99"},"PeriodicalIF":0.0,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: vitexin attenuates epithelial ovarian cancer cell viability and motility <i>in vitro</i> and carcinogenesis <i>in vivo</i> via p38 and ERK1/2 pathways related VEGFA.","authors":"Shuzhen Zhao, Xinlei Guan, Ruijie Hou, Xueying Zhang, Fang Guo, Zhifang Zhang, Caihong Hua","doi":"10.21037/atm-2022-75","DOIUrl":"10.21037/atm-2022-75","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.21037/atm-20-5586.].</p>","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"12 5","pages":"107"},"PeriodicalIF":0.0,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}